Schisandrin B

ID: schisandrin_b

Aliases: Sch B

Type: compound

Route/form: route not curated

Status: research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic, review/regulatory

Source types: preclinical, review

Linked sources: 2

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• GABAA positive allosteric modulation
• glycine receptor positive allosteric modulation
• seizure models

Optimization domains

• cognitive support
• seizure models
• GABA
• natural product

Research basis

• A 2024 paper identifies schisandrin B as a dual PAM of GABAA and glycine receptors with antiseizure effects in mouse models.
• Mechanistically useful because it connects botanical CNS claims to receptor pharmacology.

Limits, risks, and missing evidence

• Antiseizure model data do not imply general cognitive enhancement.
• GABA/glycine modulation can mean sedation, coordination, and interaction liabilities.

Risk flags

• preclinical only
• CNS depressant interactions
• limited human data
• sedation possible

Linked papers, labels, and reviews

1. Schisandrin B is a dual PAM of GABAA and glycine receptors and alleviates seizures in mouse models
   preclinical / nature_schisandrinb_gabaa_glycine_2024
   Mouse seizure models and receptor PAM mechanism.
2. A Comprehensive Review on Schisandrin B and Its Biological Properties
   review / pubmed_schisandrinb_review_2020
   Compound-level Schisandrin B review covering antioxidant, anti-inflammatory, neuroprotective, and cardioprotective mechanisms.